Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Cotinga Pharmaceuticals Inc COTQF

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.


GREY:COTQF - Post by User

Bullboard Posts
Post by Sharecropper1on Mar 05, 2017 2:22pm
251 Views
Post# 25934091

12 month $1.50 valuation is very conservative

12 month $1.50 valuation is very conservativeI've been accumulating COTI for almost a year with an average cost of .35 When I entered I was looking for .50 to 1.00 in 2016 and 5.00 to 10.00 in 2017/18. I have no reason to change my expectations. They're making haste...slowly...but the story is solid. GLTA
Bullboard Posts